Abstract
Summary
LPI (LP Information)' newest research report, the “Glanzmann Thrombasthenia Therapeutic Drug Industry Forecast” looks at past sales and reviews total world Glanzmann Thrombasthenia Therapeutic Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Glanzmann Thrombasthenia Therapeutic Drug sales for 2023 through 2029. With Glanzmann Thrombasthenia Therapeutic Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Glanzmann Thrombasthenia Therapeutic Drug industry.
This Insight Report provides a comprehensive analysis of the global Glanzmann Thrombasthenia Therapeutic Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Glanzmann Thrombasthenia Therapeutic Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Glanzmann Thrombasthenia Therapeutic Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Glanzmann Thrombasthenia Therapeutic Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glanzmann Thrombasthenia Therapeutic Drug.
The global Glanzmann Thrombasthenia Therapeutic Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Glanzmann Thrombasthenia Therapeutic Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Glanzmann Thrombasthenia Therapeutic Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Glanzmann Thrombasthenia Therapeutic Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Glanzmann Thrombasthenia Therapeutic Drug players cover Novo Nordisk, Alnylam Pharmaceuticals, Shire (Takeda), Biogen, Bioverativ (Sanofi), Bayer, CSL Behring, Grifols and Bristol-Myers Squibb, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Glanzmann Thrombasthenia Therapeutic Drug market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Platelet Transfusion
Recombinant Activated Factor VII
Antifibrinolytics
Fibrin Sealants
Thrombin
Desmopressin
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Alnylam Pharmaceuticals
Shire (Takeda)
Biogen
Bioverativ (Sanofi)
Bayer
CSL Behring
Grifols
Bristol-Myers Squibb
Pfizer
This Insight Report provides a comprehensive analysis of the global Glanzmann Thrombasthenia Therapeutic Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Glanzmann Thrombasthenia Therapeutic Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Glanzmann Thrombasthenia Therapeutic Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Glanzmann Thrombasthenia Therapeutic Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glanzmann Thrombasthenia Therapeutic Drug.
The global Glanzmann Thrombasthenia Therapeutic Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Glanzmann Thrombasthenia Therapeutic Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Glanzmann Thrombasthenia Therapeutic Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Glanzmann Thrombasthenia Therapeutic Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Glanzmann Thrombasthenia Therapeutic Drug players cover Novo Nordisk, Alnylam Pharmaceuticals, Shire (Takeda), Biogen, Bioverativ (Sanofi), Bayer, CSL Behring, Grifols and Bristol-Myers Squibb, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Glanzmann Thrombasthenia Therapeutic Drug market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Platelet Transfusion
Recombinant Activated Factor VII
Antifibrinolytics
Fibrin Sealants
Thrombin
Desmopressin
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Alnylam Pharmaceuticals
Shire (Takeda)
Biogen
Bioverativ (Sanofi)
Bayer
CSL Behring
Grifols
Bristol-Myers Squibb
Pfizer
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Glanzmann Thrombasthenia Therapeutic Drug Market Size 2018-2029
2.1.2 Glanzmann Thrombasthenia Therapeutic Drug Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Glanzmann Thrombasthenia Therapeutic Drug Segment by Type
2.2.1 Platelet Transfusion
2.2.2 Recombinant Activated Factor VII
2.2.3 Antifibrinolytics
2.2.4 Fibrin Sealants
2.2.5 Thrombin
2.2.6 Desmopressin
2.3 Glanzmann Thrombasthenia Therapeutic Drug Market Size by Type
2.3.1 Glanzmann Thrombasthenia Therapeutic Drug Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Glanzmann Thrombasthenia Therapeutic Drug Market Size Market Share by Type (2018-2023)
2.4 Glanzmann Thrombasthenia Therapeutic Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Glanzmann Thrombasthenia Therapeutic Drug Market Size by Application
2.5.1 Glanzmann Thrombasthenia Therapeutic Drug Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Glanzmann Thrombasthenia Therapeutic Drug Market Size Market Share by Application (2018-2023)
3 Glanzmann Thrombasthenia Therapeutic Drug Market Size by Player
3.1 Glanzmann Thrombasthenia Therapeutic Drug Market Size Market Share by Players
3.1.1 Global Glanzmann Thrombasthenia Therapeutic Drug Revenue by Players (2018-2023)
3.1.2 Global Glanzmann Thrombasthenia Therapeutic Drug Revenue Market Share by Players (2018-2023)
3.2 Global Glanzmann Thrombasthenia Therapeutic Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Glanzmann Thrombasthenia Therapeutic Drug by Regions
4.1 Glanzmann Thrombasthenia Therapeutic Drug Market Size by Regions (2018-2023)
4.2 Americas Glanzmann Thrombasthenia Therapeutic Drug Market Size Growth (2018-2023)
4.3 APAC Glanzmann Thrombasthenia Therapeutic Drug Market Size Growth (2018-2023)
4.4 Europe Glanzmann Thrombasthenia Therapeutic Drug Market Size Growth (2018-2023)
4.5 Middle East & Africa Glanzmann Thrombasthenia Therapeutic Drug Market Size Growth (2018-2023)
5 Americas
5.1 Americas Glanzmann Thrombasthenia Therapeutic Drug Market Size by Country (2018-2023)
5.2 Americas Glanzmann Thrombasthenia Therapeutic Drug Market Size by Type (2018-2023)
5.3 Americas Glanzmann Thrombasthenia Therapeutic Drug Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Glanzmann Thrombasthenia Therapeutic Drug Market Size by Region (2018-2023)
6.2 APAC Glanzmann Thrombasthenia Therapeutic Drug Market Size by Type (2018-2023)
6.3 APAC Glanzmann Thrombasthenia Therapeutic Drug Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Glanzmann Thrombasthenia Therapeutic Drug by Country (2018-2023)
7.2 Europe Glanzmann Thrombasthenia Therapeutic Drug Market Size by Type (2018-2023)
7.3 Europe Glanzmann Thrombasthenia Therapeutic Drug Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Glanzmann Thrombasthenia Therapeutic Drug by Region (2018-2023)
8.2 Middle East & Africa Glanzmann Thrombasthenia Therapeutic Drug Market Size by Type (2018-2023)
8.3 Middle East & Africa Glanzmann Thrombasthenia Therapeutic Drug Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.1 Global Glanzmann Thrombasthenia Therapeutic Drug Forecast by Regions (2024-2029)
10.1.1 Global Glanzmann Thrombasthenia Therapeutic Drug Forecast by Regions (2024-2029)
10.1.2 Americas Glanzmann Thrombasthenia Therapeutic Drug Forecast
10.1.3 APAC Glanzmann Thrombasthenia Therapeutic Drug Forecast
10.1.4 Europe Glanzmann Thrombasthenia Therapeutic Drug Forecast
10.1.5 Middle East & Africa Glanzmann Thrombasthenia Therapeutic Drug Forecast
10.2 Americas Glanzmann Thrombasthenia Therapeutic Drug Forecast by Country (2024-2029)
10.2.1 United States Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.2.2 Canada Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.2.3 Mexico Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.2.4 Brazil Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.3 APAC Glanzmann Thrombasthenia Therapeutic Drug Forecast by Region (2024-2029)
10.3.1 China Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.3.2 Japan Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.3.3 Korea Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.3.4 Southeast Asia Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.3.5 India Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.3.6 Australia Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.4 Europe Glanzmann Thrombasthenia Therapeutic Drug Forecast by Country (2024-2029)
10.4.1 Germany Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.4.2 France Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.4.3 UK Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.4.4 Italy Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.4.5 Russia Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.5 Middle East & Africa Glanzmann Thrombasthenia Therapeutic Drug Forecast by Region (2024-2029)
10.5.1 Egypt Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.5.2 South Africa Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.5.3 Israel Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.5.4 Turkey Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.5.5 GCC Countries Glanzmann Thrombasthenia Therapeutic Drug Market Forecast
10.6 Global Glanzmann Thrombasthenia Therapeutic Drug Forecast by Type (2024-2029)
10.7 Global Glanzmann Thrombasthenia Therapeutic Drug Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Information
11.1.2 Novo Nordisk Glanzmann Thrombasthenia Therapeutic Drug Product Offered
11.1.3 Novo Nordisk Glanzmann Thrombasthenia Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Novo Nordisk Main Business Overview
11.1.5 Novo Nordisk Latest Developments
11.2 Alnylam Pharmaceuticals
11.2.1 Alnylam Pharmaceuticals Company Information
11.2.2 Alnylam Pharmaceuticals Glanzmann Thrombasthenia Therapeutic Drug Product Offered
11.2.3 Alnylam Pharmaceuticals Glanzmann Thrombasthenia Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Alnylam Pharmaceuticals Main Business Overview
11.2.5 Alnylam Pharmaceuticals Latest Developments
11.3 Shire (Takeda)
11.3.1 Shire (Takeda) Company Information
11.3.2 Shire (Takeda) Glanzmann Thrombasthenia Therapeutic Drug Product Offered
11.3.3 Shire (Takeda) Glanzmann Thrombasthenia Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Shire (Takeda) Main Business Overview
11.3.5 Shire (Takeda) Latest Developments
11.4 Biogen
11.4.1 Biogen Company Information
11.4.2 Biogen Glanzmann Thrombasthenia Therapeutic Drug Product Offered
11.4.3 Biogen Glanzmann Thrombasthenia Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Biogen Main Business Overview
11.4.5 Biogen Latest Developments
11.5 Bioverativ (Sanofi)
11.5.1 Bioverativ (Sanofi) Company Information
11.5.2 Bioverativ (Sanofi) Glanzmann Thrombasthenia Therapeutic Drug Product Offered
11.5.3 Bioverativ (Sanofi) Glanzmann Thrombasthenia Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Bioverativ (Sanofi) Main Business Overview
11.5.5 Bioverativ (Sanofi) Latest Developments
11.6 Bayer
11.6.1 Bayer Company Information
11.6.2 Bayer Glanzmann Thrombasthenia Therapeutic Drug Product Offered
11.6.3 Bayer Glanzmann Thrombasthenia Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Bayer Main Business Overview
11.6.5 Bayer Latest Developments
11.7 CSL Behring
11.7.1 CSL Behring Company Information
11.7.2 CSL Behring Glanzmann Thrombasthenia Therapeutic Drug Product Offered
11.7.3 CSL Behring Glanzmann Thrombasthenia Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 CSL Behring Main Business Overview
11.7.5 CSL Behring Latest Developments
11.8 Grifols
11.8.1 Grifols Company Information
11.8.2 Grifols Glanzmann Thrombasthenia Therapeutic Drug Product Offered
11.8.3 Grifols Glanzmann Thrombasthenia Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Grifols Main Business Overview
11.8.5 Grifols Latest Developments
11.9 Bristol-Myers Squibb
11.9.1 Bristol-Myers Squibb Company Information
11.9.2 Bristol-Myers Squibb Glanzmann Thrombasthenia Therapeutic Drug Product Offered
11.9.3 Bristol-Myers Squibb Glanzmann Thrombasthenia Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Bristol-Myers Squibb Main Business Overview
11.9.5 Bristol-Myers Squibb Latest Developments
11.10 Pfizer
11.10.1 Pfizer Company Information
11.10.2 Pfizer Glanzmann Thrombasthenia Therapeutic Drug Product Offered
11.10.3 Pfizer Glanzmann Thrombasthenia Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Pfizer Main Business Overview
11.10.5 Pfizer Latest Developments
12 Research Findings and Conclusion